| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514010000 | Bicyclic | 16 |
| 20080242598 | Alpha Helical Mimics, Their Uses and Methods For Their Production - This invention discloses short chain peptides that have been constrained to adopt an alpha helical conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides and for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. More particularly the invention discloses alpha helical cyclic pentapeptides and their use as alpha helical scaffolds or macrocyclic alpha helical modules, either alone, or within longer chain peptides or attached to other macrocyclic peptides or attached to non-peptidic structures, for the purpose of mimicking naturally occurring peptides or proteins, and as agonists or antagonists of the biological activity of naturally-occurring peptides or proteins or for the preparation of new materials. | 10-02-2008 |
| 20080318844 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY HISTONE DEACETYLASE INHIBITORS - The present invention includes methods of treatment and compositions for treating diseases related to the activity of a histone deacetylase in a subject by administering to the subject an effective amount of a modified FK228 compound comprising an amino acid conjugate which constitutes an amino thiol, a hydroxy thiol, a dithiol, or a hydroxamic acid, instead of a hydroxy-mercapto-heptenoic acid moiety in FK228. | 12-25-2008 |
| 20090105129 | Combination therapy - The present invention relates generally to methods for inducing, promoting or otherwise facilitating pain relief. More particularly, the present invention relates to a synergistic combination of a selective inhibitor of the neuronal norepinephrine transporter and an analgesic agent in the therapeutic management of vertebrate animals, including humans, for producing analgesia or for the prevention or alleviation of pain. | 04-23-2009 |
| 20090203584 | Peptide-based Compounds - The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors. | 08-13-2009 |
| 20090264343 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 10-22-2009 |
| 20090291882 | COATINGS FOR DRUG DELIVERY DEVICES - A polymer coating for medical devices based on a polyolefin derivative. A variety of polymers are described to make coatings for medical devices, particularly, for drug delivery stents. The polymers include homo-, co-, and terpolymers having at least one olefin-derived unit and at least one unit derived from vinyl alcohol, allyl alcohol and derivatives thereof. | 11-26-2009 |
| 20090318335 | Heterodimeric Peptide Compounds Displaying Ngf Activity and Their Use to Treat Neurodegenerative Disorders - Peptides having a structure characterized by the presence of two loops constrained in cyclic structure by the presence of covalent bonds between amino acid side chains, the amino acid sequences of the first and the second loop being substantially homologues to that of loop 1 (residues 29-38) and of loop 4 (residues 92-97) of NGF, respectively, displaying nerve growth factor (NGF) agonist or partial agonist activity. | 12-24-2009 |
| 20100041591 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 02-18-2010 |
| 20100093611 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES - Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of histone deacetylase (HDAC), I | 04-15-2010 |
| 20100093612 | INTEGRIN TARGETED CYCLOPEPTIDE LIGANDS, THEIR PREPARATION AND USE - The present invention relates to novel hybrid cyclopeptide compounds embodying pyrrolidine- or piperidine-based amino acid substructures grafted onto a RGD (-Arg-Gly-Asp-) tripeptide sequence and acting as targeting ligands towards integrin receptors, intended, for example, for the treatment of altered angiogenic phenomena or for the preparation of therapeutically and/or diagnostically useful compounds; the invention also concerns a process for the synthesis of said cyclopeptides and biologically active derivatives thereof. | 04-15-2010 |
| 20100093613 | METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OR STABILIZATION OF FIBROSIS - Agents that stabilize and/or prevent fibrosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on matrix deposition and remodeling, epithelial health, and inflammation. Treatment for fibrosis is provided using compositions of the invention. | 04-15-2010 |
| 20100105609 | Processes for Preparing Eptifibatide - The present invention provides, inter alia, convergent processes for preparing eptifibatide that involve coupling a 2-6 eptifibatide fragment to an activated cysteinamide residue to form a 2-7 eptifibatide fragment, attaching a mercaptopropionic acid residue to the 2-7 eptifibatide fragment through disulfide bond formation, coupling the peptide intramolecularly, and removing the protecting group, to form eptifibatide. The invention further provides products produced by the described processes, novel compounds that can be used as synthetic intermediates for the preparation of eptifibatide, and novel compounds that are structurally similar to eptifibatide. | 04-29-2010 |
| 20100120669 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE - The present invention relates to substituted thiadiazole compounds of the formula (I): | 05-13-2010 |
| 20100152100 | ACCELERATED THERAPY - The present invention encompasses the surprising finding that romidepsin can safely be administered to humans on an accelerated dosing schedule. | 06-17-2010 |
| 20100167994 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY - Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein. | 07-01-2010 |
| 20100267634 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 10-21-2010 |
